Skip to main content
Terug
INCPF logo

InnoCare Pharma Limited

Datakwaliteit: 100%
Oversold
INCPF
OTC Healthcare Biotechnology
€ 1,55
€ 0,00 (0,00%)
Marktkapitalisatie: 2,32B
Dagbereik
€ 1,55 € 2,05
52-Weeksbereik
€ 1,55 € 3,26
Volume
1.000
50D / 200D Gem.
€ 1,85 / € 2,64
Vorige Slotkoers
€ 1,55

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -5,3 0,4
P/B 0,3 2,9
ROE % -6,4 3,7
Net Margin % -43,7 3,8
Rev Growth 5Y % 421,6 10,0
D/E 0,2 0,2

Belangrijkste Punten

Revenue grew 421,58% annually over 5 years — strong growth
Debt/Equity of 0,19 — conservative balance sheet
Negative free cash flow of -443,78M
Revenue growth is decelerating — 1Y growth trails 5Y average by 384,90%
Capital efficient — spends only 7,75% of revenue on capex

Groei

Revenue Growth (5Y)
421,58%
Revenue (1Y)36,68%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-6,35%
ROIC-4,93%
Net Margin-43,65%
Op. Margin-52,09%

Veiligheid

Debt / Equity
0,19
Current Ratio7,37
Interest Coverage-15,56

Waardering

P/E Ratio
-5,25
P/B Ratio0,34
EV/EBITDAN/A
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 36,68% Revenue Growth (3Y) 27,05%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 421,58% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,01B Net Income (TTM) -440,63M
ROE -6,35% ROA -4,68%
Gross Margin 86,29% Operating Margin -52,09%
Net Margin -43,65% Free Cash Flow (TTM) -443,78M
ROIC -4,93% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,19 Current Ratio 7,37
Interest Coverage -15,56 Dividend Yield 0,01%
Valuation
P/E Ratio -5,25 P/B Ratio 0,34
P/S Ratio 2,29 PEG Ratio 3,07
EV/EBITDA N/A Dividend Yield 0,01%
Market Cap 2,32B Enterprise Value -2,64B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1,01B 738,54M 625,40M 1,04B 1,36M
Net Income -440,63M -631,26M -886,59M -64,55M -391,40M
EPS (Diluted) -0,26 -0,37 -0,60 -0,04 -0,40
Gross Profit 871,01M 610,10M 482,01M 977,37M 1,36M
Operating Income -525,78M -651,15M -770,40M -181,10M -558,99M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 9,41B 9,92B 10,32B 7,40B 4,54B
Total Liabilities 2,66B 2,74B 2,68B 1,74B 1,38B
Shareholders' Equity 6,73B 7,15B 7,60B 5,60B 3,10B
Total Debt 1,27B 1,35B 1,25B 1,27B 1,17B
Cash & Equivalents 6,22B 8,22B 8,70B 5,93B 3,97B
Current Assets 7,82B 8,77B 9,30B 6,42B 4,09B
Current Liabilities 1,06B 2,09B 2,08B 329,30M 104,45M